FOLOTYN ® is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The indication for FOLOTYN ® is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL), based on overall response rate.

What are the possible side effects of Folotyn? FOLOTYN may cause serious side effects, including: Low Blood Cell Counts: FOLOTYN can affect your bone marrow and cause you to have low blood cell counts. Your doctor will do blood tests as needed to check your blood cell counts.

FOLOTYN is an “outpatient” treatment so you do not need to be hospitalized. It is administered as an intravenous (IV) infusion that can last up to 5 minutes.

FOLOTYN (pralatrexate injection) is a chemotherapy approved by the US Food & Drug Administration (FDA) for the treatment of relapsed or refractory PTCL. Relapsed—There was initial tumor shrinkage, but the cancer cells now resist chemotherapy and have grown again

FOLOTYN ® (pralatrexate injection) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

FOLOTYN is administered as an intravenous push over 3-5 minutes via the side port of a free-flowing 0.9% Sodium Chloride Injection, intravenous line For patients with severe renal impairment (eGFR 15 to <30 mL/min/1.73m 2), the recommended dose of FOLOTYN is …

In a heavily pretreated and relapsed/refractory population, single-agent FOLOTYN demonstrated response FOLOTYN delivered a 27% overall response rate (CR + CRu + PR) (95% CI, 19-36) in R/R PTCL 1,2

What are the possible side effects of Folotyn? FOLOTYN may cause serious side effects, including: Low Blood Cell Counts: FOLOTYN can affect your bone marrow and cause you to have low blood cell counts. Your doctor will do blood tests as needed to check your blood cell counts.

FOLOTYN ® (pralatrexate injection) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).